Weight Loss News

Diet Drug Acomplia heads to United Arab Emirates

6 June 2007

Diet Drug Rimonabant, also renowned as Acomplia and Zimulti, now will work wonder in the United Arab Emirates, according to the drug's developer, Sanofi-Aventis.

A credible support for the treatment of obesity in overweight people with cardiometabolic risk factors, the qualified drug has been available on European stores for about a year and available for purchase in Argentina, Brazil and Mexico as well. And this is the first time that it is been launched with prior announcement in the Middle East.

Under the recent survey conducted on UAE population, almost 37 percent people out of the total population are found obese, which is among the top obesity rates in the Middle East, claims the drug developer.

"Obesity is observed common among people who have excessive fat around their abdomen or who are with a high risk of developing an abnormal lipid profile, heart disease and type 2 diabetes"; said Dr. Wael Al Mahmeed, Vice President of the Emirates Cardiac Society.

"Rimonabant is a key progress in the cure of cardio-metabolic risk factors which contribute significantly to the mounting rate of diabetes and cardiovascular disease worldwide," Al Mahmeed added.